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Caveolae regulate many cardiovascular functions and thus could be of interest in relation to 26 
pre-eclampsia, a pregnancy specific disorder characterised by hypertension and proteinuria.  27 
We examined placental mRNA and protein expression/localisation of the caveolae 28 
components Caveolin 1-3, Cavin 1-4 as well as eNOS/ iNOS in normotensive control (n=24) 29 
and pre-eclamptic pregnancies (n=19). Placental mRNA expression of caveolin-1, cavin 1-3, 30 
was lower and eNOS expression was increased in pre-eclampsia (P<0.05 for all). Additionally 31 
Caveolin-1 protein expression was also reduced in pre-eclampsia (P=0.007); this could be an 32 
adaptive response in pre-eclampsia, possibly to attenuate the oxidative 33 
stress/inflammation. 34 




Introduction  37 
Pre-eclampsia is a hypertensive disorder of pregnancy. As the placenta receives no 38 
autonomic input, it relies upon vasoactive mediators to regulate its vascular reactivity. Nitric 39 
oxide (NO) plays an integral role in controlling vascular resistance within the placenta; a 40 
disruption of this pathway has been identified in pre-eclampsia [1].  NO production is 41 
catalysed by the conversion of L-arginine to NO by NO synthases (NOS), two isoforms being 42 
present in the placenta: endothelial and inducible NOS (eNOS /iNOS)[2]. 43 
Caveolae are invaginations of the plasma membrane present in most mammalian cell types 44 
[3]. Caveolins (Cav-1, Cav-2, Cav-3) and cavins (1 to 4), participate in the formation of the 45 
caveolae and the coordination of the signal transduction [4].  Cavins (adapter proteins) are 46 
responsible for caveolae assembly and Cav protein expression and stabilisation [5]. Four 47 
isoforms of cavins have been identified (cavin-1 to 4). 48 
Caveolae and Cavs, in particular Cav-1 expressed in endothelial cells (EC), have been shown 49 
to have regulatory roles in pathological angiogenesis and in vascular disease such as 50 
atherosclerosis and pulmonary hypertension [6]. Studies have confirmed protein expression 51 
of Cav-1 and 2 in the endothelium placental capillaries and syncytiotrophoblast in term 52 
human placental tissue [7-9]. Cav-1 is an organiser of redox-sensitive signalling pathways, 53 
specifically involved in reactive oxygen species (ROS)-dependent signalling events [10]. Co-54 
localisation of NADPH oxidase with eNOS in Cav-1 rich-caveolae in ECs both sustains ROS-55 




We examined placental mRNA and protein expression/localisation of the caveolae 58 




Materials and Methods 61 
Two groups of white European women (24 normotensive, 19 pre-eclamptic) were analysed; 62 
detailed demographics and outcome data have previously been published [11]. The study 63 
was approved by the Nottingham University Hospitals Ethics Committee (LREC-Q2090312) 64 
and written, informed consent was obtained. Pre-eclampsia was stringently defined as per 65 
the International Society for the Study of Hypertension in Pregnancy guidelines [12]; full 66 
depth placental tissue samples were collected [11].  67 
Evaluation of the mRNA expression was conducted as per previously published methods 68 
[11].  Immunostaining of paraffin-embedded placental sections were performed as 69 
previously described [13]. All slides were assessed by the same observers (KS-J & MRH) and 70 





The placental mRNA expression of Cav-1-3, cavin-1-4, eNOS and iNOS is presented in Figure 74 
1a-c. Cav-1 and cavin-1-3 had significantly lower expression in pre-eclamptic women (P<0.05 75 
for all; Figs. 1a & 1b) whereas Cav-2 and 3 and cavin-4 were not statistically different 76 
between groups (P> 0.05 for all).  eNOS was increased in pre-eclampsia (P = 0.045; Fig. 1c) 77 
but iNOS did not differ between groups (P> 0.05). 78 
The protein expression and localisationin placental tissue are shown in Figure. 2.  79 
Immunohistochemical staining for Cav and cavin isoforms were localised around fetal 80 
vessels and fibroblasts, with staining also in syncytiotrophoblasts. Both eNOS and iNOS 81 
expression was localised to the syncytiotrophoblast, with some staining in the endothelium. 82 
Cav-1 placental protein expression was significantly reduced in pre-eclampsia (median [IQR]: 83 
0.78 [0.73, 0.82] vs. 0.87 [0.82, 0.90] respectively; P=0.001). No significant differences were 84 
observed for any other proteins (P>0.05). 85 
 86 




This is the first report of a detailed expression profile of Cavs and cavins, together with both 89 
eNOS and iNOS in placentae from women who had pre-eclampsia. This study demonstrates 90 
that the mRNA expression of cavin-1-3 and Cav-1 are down regulated in this tissue.  eNOS 91 
mRNA is upregulated in pre-eclamptic placentae in agreement with the literature [14]. As 92 
with previous studies [15, 16], no other differences in eNOS protein expression were 93 
observed between groups. The placental localisation of Cav-1 and eNOS in this study also 94 
coincides with previous observations [7-9]. 95 
The reduction in placental Cav-1 protein expression in pre-eclamptic pregnancies may have 96 
effects on eNOS uncoupling via Angiotensin type 1 receptor (AT1R). We have previously 97 
reported increased placental AT1R protein expression in pre-eclampsia [17]; a partial down 98 
regulation in Cav-1 could reduce eNOS uncoupling through attenuation of NADPH oxidase 99 
assembly [18] and activation of eNOS in response to Angiotensin II, whilst still maintaining 100 
functional eNOS at the membrane, as has been reported in ECs [19]. This could explain why 101 
eNOS protein, but not mRNA expression, was unchanged between groups. Caveolae have 102 
been implicated as mediators of vascular inflammation, as well as determinants of 103 
intracellular redox status; the latter accomplished by facilitating the formation of ROS and 104 
decreasing NO bioavailability in response to EC injury or inflammatory stimuli [20].  105 
We have previously reported increased maternal Thiobarbituric acid reactive substances 106 
(TBARS) [11] and placental oxidative stress markers (xanthine oxidase and NADPH oxidase) 107 
[21]  and reduced placental antioxidant glutathione peroxidase activities in the women with 108 
pre-eclampsia [11]. The reduction of Cav-1 in pre-eclampsia could be an adaptive response, 109 
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independent of eNOS, to attenuate the increased oxidative stress and inflammation, as seen 110 
in models of atherosclerosis [22]. 111 
Disruption and progressive loss of Cav-1 have been associated with pulmonary hypertension 112 
outside of pregnancy [18], but detailed analysis in relation to normotensive pregnancy is 113 
sparse [7-9] and lacking altogether in pre-eclampsia. In order to determine if similar 114 
differences antedate the clinical onset of the disease, future longitudinal studies are needed 115 
to determine whether the results are cause or effect. Examination of first and second 116 
trimester placentae would enable us to trace the ontogeny of mRNA and protein expression 117 
of caveolae through pregnancy.  118 
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Figure Legends 197 
Figure 1: Normalised mRNA expression (copy number) of a) Cav-1-3; b) cavin-1-4 and c) 198 
eNOS and iNOS in placentae from normotensive and pre-eclamptic pregnancies. Boxplots 199 
represent median [interquartile range]. 200 
Figure 2: Placental protein expression and localisation of Cav-1, 2 and 3; cavin-1, 2, 3 and 4; 201 
eNOS and iNOS , in normotensive control and pre-eclamptic  women. Expression was 202 
significantly downregulated in pre-eclamptic placentae (P<0.05). Positive staining was 203 
localised mainly around fetal vessels (black arrows) with some weak staining in 204 
syncytiotrophoblasts (red arrow).  205 
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